Castle BioSciences Inc. (Castle)

Oncology Corporate Profile

HQ Location

2014 San Miguel Drive
Friendswood, TX 77546

Company Description

Castle Biosciences is a recently formed, rapidly growing, biomarker based cancer diagnostics company that is committed to bringing the promise of personalized medicine to underserved or orphan diseases.

Website: http://www.castlebiosciences.com/

Brand Generic Indication
DecisionDx-G-CIMPmolecular screening testGlioma
DecisionDx-GBMmolecular screening testGlioblastoma multiforme
DecisionDx-UMmolecular screening testUveal Melanoma

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BAP1diagnosticUveal melanoma metastasesDevelopment
DecisionDx-ECdiagnosticEsophageal cancerDevelopment
DecisionDx-GBMdiagnosticGlioblastoma Multiforme (GBM)Development
DecisionDx-ThymomadiagnosticVarious cancer typesDevelopment
DecisionDx-UMdiagnosticMelanomaDevelopment

View additional information on product candidates here »

Source: http://www.castlebiosciences.com

Recent News Headlines

Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma

5/19/2016 12:34 pm

(Yahoo! Finance) May 19, 2016 - Castle Biosciences, Inc. today announced that several abstracts on the Company’s gene expression profile (GEP) tests for cancer were accepted for poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3-7.

Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer

11/16/2015 11:38 am

(Castle Biosciences) Nov 16, 2015 - Castle Biosciences, Inc. today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis.

Castle Biosciences Presents Data on Unique Genetic Test for Predicting Cancer Recurrence in Soft Tissue Sarcoma

11/5/2015 11:46 am

(Castle Biosciences) Nov 5, 2015 - Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS).

WHO Appoints Canadian Oncologist To Help Guide Women's Cancer Care In Developing Nations

8/18/2015 12:02 pm

(Metro News Canada/The Canadian Press) Aug 17, 2015 - A Canadian oncologist has been appointed by the World Health Organization to help create guidelines and programs to provide earlier diagnosis and treatment of cancers that are killing more women in developing countries each year.

Castle Biosciences Announces National Payer Agreements with MultiPlan, FedMed and Preferred Medical Claim Solutions

6/15/2015 12:27 pm

(Yahoo! Finance) June 15, 2015 - Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx™ assays.

Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification of High Risk Disease in Tumors of Intermediate T2/T3 Thickness

6/2/2015 04:54 pm

(Morningstar) June 1, 2015 - Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced updated study results with its noninvasive gene expression profile (GEP) test, demonstrating that the assay was able to accurately identify high risk disease in patients with tumors of intermediate thickness (T2/T3), independent of sentinel lymph node biopsy (SLNB) status and ulceration.

US Sen. Warren to File Bill Targeting Top Drug Companies

1/23/2015 12:01 pm

(CNBC/Associated Press) Jan 22, 2015 - U.S. Sen. Elizabeth Warren is shifting her focus from Wall Street to the nation's top pharmaceutical companies.

BMS' Opdivo Set For Early Access in UK

1/9/2015 12:01 pm

(PMLiVE) Jan 8, 2015 - Bristol-Myers Squibb could see an early launch of its new melanoma therapy Opdivo in the UK after becoming the first drug of its class given a new fast-track status by the country's drugs regulator.

Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant to Standard Treatment of Chemoradiation Therapy

10/23/2014 12:08 pm

(Yahoo! Finance) Oct 23, 2014 - Castle Biosciences Inc. today announced that results from a second validation study of its proprietary multi-analyte test, DecisionDx-EC, confirmed the test’s ability to identify which esophageal cancer patients are unlikely to benefit from the standard pre-surgical treatment of chemoradiation.

A Survivorship Roadmap Linked to EMRs

9/10/2014 07:01 am

(ACCCBuzz) Sept 9, 2014 - In a perfect world each patient who has recently completed cancer-directed therapy should receive a survivorship care plan that clearly summarizes his or her treatment and provides direction on what to expect in the next several weeks, months, and years of their life to come.

Castle Biosciences Commercializing Tests for Orphan Cancers, Raising $11.8M

8/20/2014 12:26 pm

(MedCity News) Aug 19, 2014 - Texas cancer diagnostics company Castle Biosciences plans to expand the clinical availability of its tests that assess “rare and underserved cancers,” particularly one for cutaneous melanoma. It has wrapped up an $11.8 million round to do so, the company said.

Lacking Trust in One's Doctor Affects Health of Emotionally Vulnerable Cancer Patients

7/23/2014 06:05 am

(Center for Advancing Health/Health Behavior News Service) July 22, 2014 - A new study indicates that the physical and mental well-being of people with cancer may be affected by how they feel about their relationship with their physician and by differences in attachment styles (how they rely and depend on others).

Janssen-Cilag Gets EU Approval for Castleman’s Disease Drug

6/5/2014 12:01 pm

(MedCity News) June 4, 2014 - Belgian Janssen-Cilag International NV, part of US Johnson & Johnson, said Wednesday that Sylvant (siltuximab) had been cleared by the European Commission (EC) to treat adults with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus- 8 (HHV-8) negative.

Janssen-Cilag Gets EU Approval for Castleman’s Disease Drug

6/5/2014 07:00 am

(MedCity News) June 4, 2014 - Belgian Janssen-Cilag International NV, part of US Johnson & Johnson, said Wednesday that Sylvant (siltuximab) had been cleared by the European Commission (EC) to treat adults with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus- 8 (HHV-8) negative.

Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease in a Cohort of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy

6/3/2014 03:26 pm

(Yahoo! Finance) June 2, 2014 - Castle Biosciences Inc. today announced results of a 217-patient study demonstrating that its gene expression profile (GEP) test, DecisionDx-Melanoma, identified primary cutaneous (skin) melanoma tumors that were sentinel lymph node biopsy negative but were at high risk of metastasis.

Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease in a Cohort of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy

6/3/2014 10:02 am

(Yahoo! Finance) June 2, 2014 - Castle Biosciences Inc. today announced results of a 217-patient study demonstrating that its gene expression profile (GEP) test, DecisionDx-Melanoma, identified primary cutaneous (skin) melanoma tumors that were sentinel lymph node biopsy negative but were at high risk of metastasis.

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

6/1/2014 01:05 pm

(Morningstar Advisor) June 1, 2014 - Nektar Therapeutics announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers.

Castle Biosciences' Esophageal Cancer Test Accurately Predicts Pre-Surgical Treatment Response

5/31/2014 05:50 pm

(NEWS.GNOM.ES) May 31, 2014 - Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

Castle Biosciences' Esophageal Cancer Test Accurately Predicts Pre-Surgical Treatment Response

5/31/2014 12:05 pm

(NEWS.GNOM.ES) May 31, 2014 - Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

Castle Biosciences' Esophageal Cancer Test Identifies Patients Who Are Resistant to Standard Pre-Surgical Chemoradiation Therapy

5/6/2014 12:13 pm

(Yahoo! Finance) May 6, 2014 - Castle Biosciences Inc. announced that data from two clinical validation studies of its DecisionDx-EC multi-biomarker test were reviewed in an oral presentation at the Digestive Disease Week (DDW) Annual Meeting.

Castle Biosciences' Esophageal Cancer Test Identifies Patients Who Are Resistant to Standard Pre-Surgical Chemoradiation Therapy

5/6/2014 07:01 am

(Yahoo! Finance) May 6, 2014 - Castle Biosciences Inc. announced that data from two clinical validation studies of its DecisionDx-EC multi-biomarker test were reviewed in an oral presentation at the Digestive Disease Week (DDW) Annual Meeting.

Castle Biosciences' Mesothelioma Molecular Test Accurately Stratifies Survival Risk Under Surgical and Non-Surgical Treatment Plans

4/29/2014 12:13 pm

(Yahoo! Finance) Apr 29, 2014 - Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94th Annual Meeting.

Castle Biosciences' Mesothelioma Molecular Test Accurately Stratifies Survival Risk Under Surgical and Non-Surgical Treatment Plans

4/29/2014 07:01 am

(Yahoo! Finance) Apr 29, 2014 - Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94th Annual Meeting.

FDA Approves Sylvant for Rare Castleman’s Disease

4/24/2014 06:42 am

(FDA.gov) Apr 23, 2014 - The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).

FDA Approves Sylvant for Rare Castleman’s Disease

4/24/2014 06:04 am

(FDA.gov) Apr 23, 2014 - The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).

Castle Biosciences’ Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients

3/24/2014 12:12 pm

(Castle Biosciences) Mar 22, 2014 – Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy.

Castle Biosciences’ Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients

3/24/2014 12:01 pm

(Castle Biosciences) Mar 22, 2014 – Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy.

Castle Biosciences Announces Data Demonstrating Ability to Identify Esophageal Cancer Patients Resistant to Standard Pre-Surgical Treatment of Chemotherapy and Radiation

1/16/2014 11:59 am

(San Francisco Business Times) Jan 16, 2014 - Castle Biosciences today announced that study results of a proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard pre-surgical treatment of chemotherapy and radiation.

Castle Biosciences Announces Data Demonstrating Ability to Identify Esophageal Cancer Patients Resistant to Standard Pre-Surgical Treatment of Chemotherapy and Radiation

1/16/2014 11:05 am

(San Francisco Business Times) Jan 16, 2014 - Castle Biosciences today announced that study results of a proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard pre-surgical treatment of chemotherapy and radiation.

Siltuximab Pivotal Trial Data Show Efficacy for Treatment of Patients with Multicentric Castleman's Disease

12/8/2013 05:16 pm

(Yahoo! Finance) Dec 8, 2013 – Siltuximab regulatory filing granted priority review by the United States Food and Drug Administration.

Siltuximab Pivotal Trial Data Show Efficacy for Treatment of Patients with Multicentric Castleman's Disease

12/8/2013 05:01 pm

(Yahoo! Finance) Dec 8, 2013 – Siltuximab regulatory filing granted priority review by the United States Food and Drug Administration.

Texas Biotech Firm Castle Biosciences Launches Tissue Repository for Eye Cancer Patients

10/2/2013 11:35 am

(BioNews Texas) Oct 1, 2013 - Castle Biosciences Inc. announced Monday the availability of a tumor tissue repository for patients whose tumors are being tested with the Company’s gene test for uveal melanoma.

Texas Biotech Firm Castle Biosciences Launches Tissue Repository for Eye Cancer Patients

10/2/2013 11:03 am

(BioNews Texas) Oct 1, 2013 - Castle Biosciences Inc. announced Monday the availability of a tumor tissue repository for patients whose tumors are being tested with the Company’s gene test for uveal melanoma.

Genetic Test Highly Accurate in Differentiating Thymomas From Thymic Carcinoma Tumors

9/25/2013 11:05 am

(MarketWatch) Sep 25, 2013 - Castle Biosciences Inc. today announced data from a study of a genetic test demonstrating high accuracy in differentiating thymomas from thymic carcinoma tumors.

Age May Be a Factor in Melanoma Treatment Quality

8/22/2013 10:05 am

(Reuters Health) Aug 21, 2013 - People over age 70 diagnosed with melanoma may wait longer to have the malignant spot removed and receive less comprehensive care and monitoring than younger patients, a French study suggests.

Rare Leukaemia Survival Rate Breakthrough

8/13/2013 11:05 am

(Newcastle University [Newcastle upon Tyne, UK]) Aug 13, 2013 - A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

Gene Test Identifies Non-Metastatic Melanoma Patients at High Risk of Recurrence

8/2/2013 11:02 am

(Sacramento Bee) Aug 2, 2013 - Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the American Academy of Dermatology (AAD).

New Website Dedicated to Patients with Thymic Cancer

7/29/2013 12:00 pm

(San Antonio Business Journal) July 29, 2013 - Castle Biosciences Inc., a leading developer of diagnostic and prognostic tests for rare cancers, announced today the launch of ThymicCancer.com, a website created to educate patients, their families and healthcare providers about the two main types of this rare, and sometimes aggressive, cancer of the thymus gland.

American Society of Clinical Oncology (ASCO) Certifies Regional Cancer Care Associates - Central Jersey Division for Providing the Highest Standards of Care

6/13/2013 11:01 am

(Yahoo! Finance) June 12, 2013 - Regional Cancer Care Associates LLC - Central Jersey Division, a member of one of the nation’s largest oncology physician networks, has been recognized by the world’s leading oncology professional organization for providing the highest-standard of cancer care.

Castle Biosciences Announces Availability of DecisionDx-Melanoma Test to Identify Stage I & II Melanoma Patients at High Risk of Metastasis

6/3/2013 06:20 pm

(Yahoo! Finance) June 3, 2013 - Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #9022).

Castle Biosciences Announces Availability of DecisionDx-Melanoma Test to Identify Stage I & II Melanoma Patients at High Risk of Metastasis

6/3/2013 06:02 pm

(Yahoo! Finance) June 3, 2013 - Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #9022).

Lack of Evidence on Oral Cancer Screening: Panel

4/9/2013 09:02 am

(Yahoo! News/Reuters Health) Apr 9, 2013 - There is not enough evidence to recommend for or against screening for oral cancer, a government-backed panel said today, due to a lack of data on possible benefits and harms tied to screening.

Drug Costs And Pricing Issues Touch Hospitals, Independent Pharmacies

4/4/2013 04:02 pm

(Kaiser Health News) Mar 28, 2013 - NPR reports on how one hospital made what is termed an "unusual decision" -- it chose to not stock a new drug because it was very costly.